Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. (GLSI): 18 pipeline candidates · 17 upcoming catalysts · ~7 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
6.7 months
D/E 0.99 · 0% dilution
Lead: Approved
18 candidates
17 upcoming, next in ~30d
4 buys · 0 sells (180d)
A transparent, data-derived signal for Greenwich LifeSciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$345.5M
Cash
$10.5M
Quarterly Burn
$4.7M
Runway
6.7 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (18 candidates)
| Drug | Phase |
|---|---|
| acetazolamide | Approved |
| azithromycin | Approved |
| baclofen | Approved |
| candesartan cilexetil | Approved |
| clindamycin | Approved |
| diclofenac | Approved |
| glsi-100 | Phase 3 |
| ibrutinib | Approved |
| ibuprofen | Approved |
| lidocaine | Approved |
Showing 10 of 18 candidates. Sign up for full pipeline.
Upcoming Catalysts (17)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
62
Total value held
$45.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 596,532 | $14.3M |
| blackrock, inc. | 433,860 | $10.4M |
| geode capital management, llc | 155,466 | $3.7M |
| state street corp | 133,875 | $3.2M |
| northern trust corp | 75,125 | $1.8M |
| vanguard portfolio management llc | 58,911 | $1.4M |
| bank of new york mellon corp | 46,523 | $1.1M |
| vanguard fiduciary trust co | 44,908 | $1.1M |
| goldman sachs group inc | 39,521 | $949K |
| ancora advisors llc | 37,500 | $901K |
Showing top 10 of 62 institutional holders of Greenwich LifeSciences, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Greenwich LifeSciences, Inc.'s pipeline?
Greenwich LifeSciences, Inc. (GLSI) has 18 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Greenwich LifeSciences, Inc.'s lead drug candidate?
Greenwich LifeSciences, Inc.'s most advanced tracked candidate is acetazolamide (Approved) for INDICATIONS AND USAGE For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide Tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attem.
What is Greenwich LifeSciences, Inc.'s next catalyst?
Greenwich LifeSciences, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: DUEXIS" — expected July 18, 2026.
What is Greenwich LifeSciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Greenwich LifeSciences, Inc. has approximately 6.7 months of cash runway.
What is Greenwich LifeSciences, Inc.'s market capitalization?
Greenwich LifeSciences, Inc.'s market capitalization is approximately $345.5M.
Get the full picture on Greenwich LifeSciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.